Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Cipher reports net revenue of $1.1 million for 2010 third quarter

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three and nine months ended September 30, 2010.

27 Oct 2010

New International malaria research consortium to develop novel classes of antimalarials

Research teams from three academic institutions and two private sector companies on two continents have come together to form the International malaria research consortium for the development of novel classes of antimalarials. This bold initiative will develop novel classes of drugs against malaria, a deadly disease in desperate need of new treatments.

27 Oct 2010

Oramed to present data on oral insulin formulation for Type II diabetes at Annual Meeting in Bethesda

Oramed Pharmaceuticals Inc. a developer of oral drug delivery systems, announced today that its work entitled "Extended exposure to an oral insulin formulation yields decreased insulin secretion in Type II diabetes subjects," will be presented at the Tenth Annual Meeting of the Diabetes Technology Society, to be held in Bethesda, Maryland this November.

27 Oct 2010

Agile presents AG200-15 contraceptive patch Phase 2 clinical study results at 66th ASRM

Agile Therapeutics announced results today from a Phase 2 clinical study of AG200-15, Agile's weekly contraceptive patch containing ethinyl estradiol (EE) in combination with levonorgestrel (LNG). According to the clinical findings, AG200-15 provides a low daily dose of estrogen equivalent to 30 micrograms EE, similar to that in low-dose, oral contraceptive (OC) pills.

26 Oct 2010

TransPharma announces positive results of ViaDerm-hPTH Phase 1 trial for osteoporosis treatment

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today successful results of a 4 week Phase 1 trial of its new self-applied ViaDerm-hPTH(1-34) for the treatment of osteoporosis.

26 Oct 2010

Soligenix reports Phase 2 clinical trial results of orBec for GVHD

Soligenix, Inc. a late-stage biopharmaceutical company, today reported preliminary results from its Phase 2 "proof-of-concept" exploratory clinical trial of orBec for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation (HCT) and continuing through the post-transplantation period.

25 Oct 2010

Inovio announces publication of minimally-invasive intradermal device in journal Gene Therapy

Inovio Pharmaceuticals, Inc. a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a peer-reviewed research article describing the development of a new intradermal, minimally-invasive DNA vaccine delivery device was published in the prestigious journal Gene Therapy.

25 Oct 2010

Kanto Chemical to distribute NanoIntegris' carbon nanotubes in Japan

NanoIntegris, Inc. announced today that it entered into a distribution contract with Kanto Chemical Co., Inc. NanoIntegris is the world's only supplier of 99% enriched metallic and semiconducting single-walled carbon nanotubes. Research companies and universities are currently using NanoIntegris' carbon nanotubes to develop emerging technologies such as printable transistors, chemical sensors, and biomedical applications such as imaging and drug delivery.

25 Oct 2010

Novartis informs Emisphere on First Interpretable Results of two-year Phase III Study 2301 in osteoarthritis

Emisphere Technologies, Inc. announced today that Novartis Pharma AG provided Emisphere with information regarding the First Interpretable Results of the two-year Phase III Study 2301 in osteoarthritis conducted by its license partner Nordic Bioscience with oral calcitonin (SMC021).

25 Oct 2010

Diamyd Medical to divide operations into two business areas

In her comments in today's year end report, Elisabeth Lindner, President and CEO of Diamyd Medical, states that the company has decided to divide its operations into two business areas beginning with the new 2010/2011 fiscal year; Diabetes and Pain.

22 Oct 2010

Hospira announces launch of piperacillin and tazobactam injection in the US

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced the launch of piperacillin and tazobactam for injection in the United States. The medication is a generic version of Zosyn, the world's leading injectable antibiotic, from Pfizer. Piperacillin and tazobactam injection posted 2009 U.S. sales of more than $855 million.

22 Oct 2010

Dicerna secures $4 million in second closing of Series B equity financing

Dicerna Pharmaceuticals, Inc. a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology and Dicer Substrate siRNA (DsiRNA) molecules, today announced a second closing of its Series B equity financing, securing an additional $4 million and bringing the total capital raised in this round to $29 million.

22 Oct 2010

Baxter third quarter net income increases 12% to $595 million

Baxter International Inc. today announced its financial results for the third quarter of 2010, and provided its fourth quarter and updated full-year 2010 financial outlook.

From Baxter International Inc. 21 Oct 2010

New PharmaDeals v4 online resource to support pharmaceutical industry

In the current BioPharma economic climate; with smaller companies desperately needing the right development partners for survival and larger ones needing to support their existing businesses through making the right deals, having the best, most comprehensive, intelligence and insights are absolutely essential for success.

21 Oct 2010

$OptiNose reports positive results from study of fluticasone delivered by novel device in refractory CRS$

OptiNose reports positive results from study of fluticasone delivered by novel device in refractory CRS

Today OptiNose Inc. announced the positive results of a study evaluating the efficacy of fluticasone when delivered by the Company's novel bi-directional technology in patients with refractory chronic rhinosinusitis (CRS). The results of the study have been published in an article in the September issue of Rhinology.

21 Oct 2010

Access submits additional patent applications for Cobalamin-mediated oral drug delivery technology

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has submitted additional patent applications, covering its Cobalamin-mediated oral drug delivery technology formulations of many global top-100 injectable drugs, as a result of the growing interest surrounding the company's proprietary oral delivery technology.

21 Oct 2010

Generex announces participation in Annual Canadian Diabetes Association Conference

Generex Biotechnology Corporation today announced that it will be attending the 13th Annual Canadian Diabetes Association (CDA)/ Canadian Society of Endocrinology and Metabolism (CSEM)Professional Conference and Annual Meetings in Edmonton, Alberta. The gathering will run from October 20-23, 2010 at the Shaw Conference Centre.

21 Oct 2010

BREAKYL drug receives European approval

BioDelivery Sciences International, Inc. and Meda today announced approval of BEMA Fentanyl in Europe via the Decentralized Procedure, with Germany acting as Reference Member State.

20 Oct 2010

Particle Sciences enters licensing, technology agreement with Solubest

Particle Sciences Inc. (PSI), a leading pharmaceutical CRO and SoluBest have entered into a licensing and technology development agreement. Under the agreement, Particle Sciences will be the exclusive contract research provider in the U.S. for SoluBest's Solumer technology.

20 Oct 2010

En Ze Jia Shi Pharmaceuticals receives patent for controlled-release oral gliclazide

Lotus Pharmaceuticals, Inc.a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China announced today that its wholly owned subsidiary, En Ze Jia Shi Pharmaceuticals, has been issued a patent by the State Intellectual Property Office of the People's Republic of China for controlled-release oral gliclazide. The patent covers the composition and preparation methods for the drug through 2030.

20 Oct 2010

Drug Delivery News and Research

Further Reading

Cipher reports net revenue of $1.1 million for 2010 third quarter

New International malaria research consortium to develop novel classes of antimalarials

Oramed to present data on oral insulin formulation for Type II diabetes at Annual Meeting in Bethesda

Agile presents AG200-15 contraceptive patch Phase 2 clinical study results at 66th ASRM

TransPharma announces positive results of ViaDerm-hPTH Phase 1 trial for osteoporosis treatment

Soligenix reports Phase 2 clinical trial results of orBec for GVHD

Inovio announces publication of minimally-invasive intradermal device in journal Gene Therapy

Kanto Chemical to distribute NanoIntegris' carbon nanotubes in Japan

Novartis informs Emisphere on First Interpretable Results of two-year Phase III Study 2301 in osteoarthritis

Diamyd Medical to divide operations into two business areas

Hospira announces launch of piperacillin and tazobactam injection in the US

Dicerna secures $4 million in second closing of Series B equity financing

Baxter third quarter net income increases 12% to $595 million

New PharmaDeals v4 online resource to support pharmaceutical industry

OptiNose reports positive results from study of fluticasone delivered by novel device in refractory CRS

Access submits additional patent applications for Cobalamin-mediated oral drug delivery technology

Generex announces participation in Annual Canadian Diabetes Association Conference

BREAKYL drug receives European approval

Particle Sciences enters licensing, technology agreement with Solubest

En Ze Jia Shi Pharmaceuticals receives patent for controlled-release oral gliclazide

Developing a best-in-class, end-to-end CMC platform eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo